Loading...
XETREUZ
Market cap966mUSD
Dec 23, Last price  
44.56EUR
1D
-0.04%
1Q
3.20%
Jan 2017
560.15%
IPO
1,788.14%
Name

Eckert & Ziegler Strahlen und Medizintechnik AG

Chart & Performance

D1W1MN
XETR:EUZ chart
P/E
35.32
P/S
3.77
EPS
1.26
Div Yield, %
1.12%
Shrs. gr., 5y
0.15%
Rev. gr., 5y
7.84%
Revenues
246m
+10.72%
35,533,00041,792,0000071,612,000101,399,000111,093,000116,197,000119,997,000117,138,000127,256,000140,046,000137,935,000138,631,000168,709,000178,493,000176,140,000180,435,000222,260,000246,092,000
Net income
26m
-10.17%
3,426,0001,590,000003,037,00021,892,00010,415,00011,415,00010,293,0009,089,0006,775,00010,718,0009,550,00014,701,00016,133,00022,019,00021,287,00034,527,00029,278,00026,300,000
CFO
47m
+36.88%
2,559,0003,531,0006,919,0008,291,0008,566,00022,112,00015,025,00020,159,00016,574,00014,649,00010,653,00016,230,00019,832,00026,827,00021,210,00040,429,00036,787,00033,855,00034,298,00046,947,000
Dividend
Jun 27, 20240.05 EUR/sh
Earnings
Mar 20, 2025

Profile

Eckert & Ziegler Strahlen- und Medizintechnik AG, through its subsidiaries, manufactures and sells isotope technology components for medical, scientific, and industrial applications worldwide. It operates in two segments, Medical and Isotope Products. The Medical segment offers small radioactive implants for the treatment of prostate cancer seeds; and eye application based on ruthenium-106 or iodine-125 for treating uveal melanoma. This segment also provides radiopharmaceuticals, laboratory equipment, hot cells, and services for radiopharmaceuticals, as well as eye applicators and prostate implants. The Isotope Products segment manufactures and sells radiation sources for imaging, measurement technology, material analysis, quality assurance, and environmental monitoring. This segment also offers calibration sources for medical imaging systems, and homeland security and radiometric level measurement products. The company was founded in 1992 and is headquartered in Berlin, Germany.
URL
https://www.ezag.com/
IPO date
Feb 25, 2008
Employees
1,036
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
246,092
10.72%
222,260
23.18%
180,435
2.44%
Cost of revenue
158,835
142,326
113,740
Unusual Expense (Income)
NOPBT
87,257
79,934
66,695
NOPBT Margin
35.46%
35.96%
36.96%
Operating Taxes
11,824
13,256
11,729
Tax Rate
13.55%
16.58%
17.59%
NOPAT
75,433
66,678
54,966
Net income
26,300
-10.17%
29,278
-15.20%
34,527
62.20%
Dividends
(10,406)
(10,382)
(9,323)
Dividend yield
Proceeds from repurchase of equity
149
BB yield
Debt
Debt current
8,948
2,690
10,130
Long-term debt
77,272
74,084
36,728
Deferred revenue
2,005
2,250
2,452
Other long-term liabilities
80,895
82,945
73,238
Net debt
(13,889)
(20,139)
(61,887)
Cash flow
Cash from operating activities
46,947
34,298
33,855
CAPEX
(26,276)
(31,130)
(28,855)
Cash from investing activities
(42,745)
(41,043)
(23,588)
Cash from financing activities
(9,283)
(5,707)
(6,059)
FCF
15,530
30,796
37,049
Balance
Cash
67,998
82,701
95,017
Long term investments
32,111
14,212
13,728
Excess cash
87,804
85,800
99,723
Stockholders' equity
160,468
150,592
132,529
Invested Capital
275,493
257,574
187,886
ROIC
28.30%
29.94%
32.52%
ROCE
23.93%
22.94%
23.01%
EV
Common stock shares outstanding
20,824
20,798
20,753
Price
Market cap
EV
EBITDA
100,631
90,914
76,290
EV/EBITDA
Interest
3,993
1,773
1,195
Interest/NOPBT
4.58%
2.22%
1.79%